The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS.

Ananyeva LP, Starovoytova MN, Gaydukova IZ, Lukina GV, Zonova EV, Eliseeva LV, Fatkhullina GF, Abdulganieva DI, Krechikova DG, Kropotina TV, Nesmeyanova OB, Vinogradova IB, Zhugrova ES, Ivanova LV, Nikulenkova NE, Ziganshin OR, Plaksina TV, Zlobin MV, Grabovetskaya YY, Soroka NF, Ershova OB, Povarova TV, Anoshenkova ON, Lutsky AA, Zinkina-Orikhan AV, Linkova YN, Fokina EA, Porozova AA, Pukhtinskaya PS, Eremeeva AV

Open source

DOI: 10.1134/s1607672926700018
Published: 2026 Jun
Container: Doklady. Biochemistry and biophysics
Publisher: Not recorded
Open access: no

Credibility signals

limited evidence Score 43/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1134/s1607672926700018,
  title = {The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS.},
  author = {Ananyeva LP and Starovoytova MN and Gaydukova IZ and Lukina GV and Zonova EV and Eliseeva LV and Fatkhullina GF and Abdulganieva DI and Krechikova DG and Kropotina TV and Nesmeyanova OB and Vinogradova IB and Zhugrova ES and Ivanova LV and Nikulenkova NE and Ziganshin OR and Plaksina TV and Zlobin MV and Grabovetskaya YY and Soroka NF and Ershova OB and Povarova TV and Anoshenkova ON and Lutsky AA and Zinkina-Orikhan AV and Linkova YN and Fokina EA and Porozova AA and Pukhtinskaya PS and Eremeeva AV},
  year = {2026},
  journal = {Doklady. Biochemistry and biophysics},
  doi = {10.1134/s1607672926700018},
  url = {https://doi.org/10.1134/s1607672926700018}
}

RIS

TY  - JOUR
TI  - The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS.
AU  - Ananyeva LP
AU  - Starovoytova MN
AU  - Gaydukova IZ
AU  - Lukina GV
AU  - Zonova EV
AU  - Eliseeva LV
AU  - Fatkhullina GF
AU  - Abdulganieva DI
AU  - Krechikova DG
AU  - Kropotina TV
AU  - Nesmeyanova OB
AU  - Vinogradova IB
AU  - Zhugrova ES
AU  - Ivanova LV
AU  - Nikulenkova NE
AU  - Ziganshin OR
AU  - Plaksina TV
AU  - Zlobin MV
AU  - Grabovetskaya YY
AU  - Soroka NF
AU  - Ershova OB
AU  - Povarova TV
AU  - Anoshenkova ON
AU  - Lutsky AA
AU  - Zinkina-Orikhan AV
AU  - Linkova YN
AU  - Fokina EA
AU  - Porozova AA
AU  - Pukhtinskaya PS
AU  - Eremeeva AV
PY  - 2026
JO  - Doklady. Biochemistry and biophysics
DO  - 10.1134/s1607672926700018
UR  - https://doi.org/10.1134/s1607672926700018
ER  -

APA

LP, A., MN, S., IZ, G., GV, L., EV, Z., LV, E., GF, F., DI, A., DG, K., TV, K., OB, N., IB, V., ES, Z., LV, I., NE, N., OR, Z., TV, P., MV, Z., YY, G., NF, S., OB, E., TV, P., ON, A., AA, L., AV, Z., YN, L., EA, F., AA, P., PS, P., & AV, E. (2026). The Efficacy and Safety of Divozilimab in Patient with Systemic Sclerosis: 48-Week Results of the Randomized Double-Blind Placebo-Controlled Phase III Clinical Study LIBERIUS.. Doklady. Biochemistry and biophysics. https://doi.org/10.1134/s1607672926700018

Source records

pubmed · retrieved 2026-09-26T09:20:23.831Z
europe-pmc · retrieved 2026-09-26T09:20:23.846Z